Trial Profile
A Long-Term, Open-Label Study Of CP-690,550 To Confirm The Safety Following Long Term Administration Of CP-690,550 In The Treatment Of Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational
- Sponsors Pfizer
- 09 Nov 2021 Results of post hoc analyses from RCT data: Cohort C, (NCT00814307, NCT02187055); C2, (NCT01039688); and C3, (NCT00413699, NCT00661661) assessing the patient characteristics, efficacy, and treatment patterns for tofacitinib monotherapy in patient with rheumatoid arthritis using RCT data and available RWD, presented at the ACR Convergence 2021.
- 05 Jun 2021 Results (n=2265) of post-hoc analysis from three trials (NCT00847613; NCT00853385, NCT00856544, NCT00661661 and NCT00413699) assessing the impact of sex on efficacy, safety and persistence in tofacitinib rheumatoid arthritis presented at the 22nd Annual Congress of the European League Against Rheumatism
- 24 Oct 2018 Results of pooled data 2 LTE studies (NCT00413699 [ORAL Sequel LTE main study database locked at time of analysis: March 2017] and NCT00661661) assessing patient Characteristics Associated with Discontinuation of Tofacitinib, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.